BD is combining its Biosciences and Diagnostic Solutions business with Waters Corporation in a deal valued at approximately $17.5 billion. The merger will form a new company focused on regulated testing markets, with projected 2025 revenues of $6.5 billion.
The partnership brings together Waters’ strengths in liquid chromatography, mass spectrometry, and analytical instrumentation with BD’s regulatory expertise and presence in clinical diagnostics. The companies say the move will enhance innovation, market access, and automation in high-growth life science and diagnostic sectors.
Waters CEO Udit Batra will lead the newly formed company, with senior leaders from both businesses expected to take on key roles.
Read the full story here.
